HIV Immunocapture Reveals Particles Expressed in Semen Under Integrase Strand Transfer Inhibitor-Based Therapy Are Largely Myeloid Cell-Derived and Disparate

• Published in: The Journal of infectious diseases 2024-07, Vol.230 (1), p.78-85
• Main Authors: Johnson, Jeffrey A, Li, Jin-Fen, Politch, Joseph A, Lipscomb, Jonathan T, Tino, Ariana Santos, DeFelice, Jason, Gelman, Marcy, Anderson, Deborah J, Mayer, Kenneth H
• Format: Article
• Language: English
• Subjects: Adult; HIV Infections - drug therapy; HIV Infections - virology; HIV Integrase Inhibitors - pharmacology; HIV Integrase Inhibitors - therapeutic use; HIV-1 - drug effects; HIV-1 - genetics; Humans; Male; Middle Aged; Phylogeny; RNA, Viral - genetics; Semen - virology; Virion - metabolism
• ISSN: 0022-1899; 1537-6613; 1537-6613
• DOI: 10.1093/infdis/jiae073

As use of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI) increases and formulations are being developed for maintenance therapies and chemoprophylaxis, assessing virus suppression under INSTI-based regimens in prevention-relevant biologic compartments, such as the male genital tract, is timely. We used cell-source marker virion immunocapture to examine amplification of particle RNA then assessed the phylogenetic relatedness of seminal and blood viral sequences from men with HIV who were prescribed INSTI-based regimens. Seminal plasma immunocaptures yielded amplifiable virion RNA from 13 of 24 (54%) men, and the sequences were primarily associated with markers indicative of macrophage and resident dendritic cell sources. Genetic distances were greatest (>2%) between seminal virions and circulating proviruses, pointing to ongoing low-level expression from tissue-resident cells. While the low levels in semen predict an improbable likelihood of transmission, viruses with large genetic distances are expressed under potent INSTI therapy and have implications for determining epidemiologic linkages if adherence is suboptimal.